Trial reportDiabetes care2019
Visit-to-Visit Glycemic Variability and Risks of Cardiovascular Events and All-Cause Mortality: The ALLHAT Study.
Trial report in Diabetes care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed.
- Empagliflozin reduced long-term HbA1c variability and cardiovascular death: insights from the EMPA-REG OUTCOME trial.Cardiovascular diabetology · 2020Trial
- Association of Long-term Change and Variability in Glycemia With Risk of Incident Heart Failure Among Patients With Type 2 Diabetes: A Secondary Analysis of the ACCORD Trial.Diabetes care · 2020Trial
- An Inverted U-shaped Relationship between Glycemic Variability and Mortality in Patients with Severe Pulmonary Embolism: A Retrospective Study.Journal of atherosclerosis and thrombosis · 2026Article
- Association between stress hyperglycemia ratio and mortality of traumatic brain injury patients based on MIMIC-IV and eICU databases.BMC neurology · 2026Article
- Factors Associated With Predialysis Plasma Glucose Variability in Patients With Diabetes on Hemodialysis.International journal of endocrinology · 2026Article
- Article
- In-Hospital Glycemic Variability and Mean Blood Glucose as Risk Markers for Long-Term Mortality in Patients with Diabetes.Journal of clinical medicine · 2025Article
- Fasting plasma glucose trajectories are associated with ischemic stroke in the elderly: a longitudinal study using group-based trajectory modeling in Chinese communities.BMC public health · 2025Article
- The prognostic role of glycemic variability in predicting the risk of adverse cardiovascular events in patients with cardiovascular diseases: a meta-analysis.Diabetology & metabolic syndrome · 2025Review
- Interplay of glycated hemoglobin and traditional risk factors for the risk of atherosclerotic cardiovascular disease and all-cause mortality in people without diabetes.Cardiovascular diabetology · 2025Observational
- Influence of fluctuations in fasting blood glucose on left ventricular function in patients with type 2 diabetes mellitus and coronary microcirculation dysfunction: a prospective cohort study.Acta diabetologica · 2025Article
- Enhancing Cardiovascular Risk Prediction in Type 2 Diabetes: The Role of NT-proBNP as a Prognostic Biomarker.Cureus · 2025Review
- The prognostic association of triglyceride-glucose index and its derived indicators with stable coronary artery disease patients undergoing percutaneous coronary intervention.Frontiers in endocrinology · 2025Article
- Association between mean HbA1c, HbA1c variability, and severity of coronary artery disease using SYNTAX score in patients with type 2 diabetes.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025Article
- A retrospective analysis of the prognostic implications of glycemic variability on all-cause mortality in critically ill patients with mitral valve disease.Frontiers in endocrinology · 2025Article
- Higher Clinical Frailty Scale is Associated with Higher Visit-to-Visit Glycated Hemoglobin (HbA1c) Variability in Patients with Type 2 Diabetes Mellitus: A Propensity Score-Matched Study.Clinical interventions in aging · 2025Article
- Prognostic value of mean glycemia and glycemic variability in medical, surgical, and cardiovascular intensive care units at a Lebanese tertiary care center.Frontiers in endocrinology · 2025Article
- Clinical implications and pharmacological considerations of glycemic variability in patients with type 2 diabetes mellitus.Scientific reports · 2024Article
- Ageing well with diabetes: the role of technology.Diabetologia · 2024Review
- The association between index-year, average, and variability of the triglyceride-glucose index with health outcomes: more than a decade of follow-up in Tehran lipid and glucose study.Cardiovascular diabetology · 2024Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe prognostic value of long-term glycemic variability is incompletely understood. We evaluated the influence of visit-to-visit variability (VVV) of fasting blood glucose (FBG) on incident cardiovascular disease (CVD) and mortality. RESEARCH DESIGN AND
methodsWe conducted a prospective cohort analysis including 4,982 participants in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) who attended the baseline, 24-month, and 48-month visits. VVV of FBG was defined as the SD or variability independent of the mean (VIM) across FBG measurements obtained at the three visits. Participants free of CVD during the first 48 months of the study were followed for incident CVD (coronary heart disease [CHD], stroke, and heart failure [HF]) and all-cause mortality.
resultsOver a median follow-up of 5 years, there were 305 CVD events (189 CHD, 45 stroke, and 81 HF) and 154 deaths. The adjusted hazard ratio (HR) comparing participants in the highest versus lowest quartile of SD of FBG (≥26.4 vs. <5.5 mg/dL) was 1.43 (95% CI 0.93-2.19) for CVD and 2.22 (95% CI 1.22-4.04) for all-cause mortality. HR for VIM was 1.17 (95% CI 0.84-1.62) for CVD and 1.89 (95% CI 1.21-2.93) for all-cause mortality. Among individuals without diabetes, the highest quartile of SD of FBG (HR 2.67 [95% CI 0.14-6.25]) or VIM (HR 2.50 [95% CI 1.40-4.46]) conferred a higher risk of death.
conclusionsGreater VVV of FBG is associated with increased mortality risk. Our data highlight the importance of achieving normal and consistent glycemic levels for improving clinical outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.